Glycaemic management of type 2 diabetes

Type 2 diabetes mellitus (T2DM) is a chronic multifactorial disorder associated with hyperglycaemia and long-term end-organ damage. This end-organ damage is due to hyperglycaemia and the accompanying risk factors such as hypertension, dyslipidaemia and obesity, leading to increased risk of cardiovascular disease and mortality. It is essential to adopt effective multifactorial risk reduction strategies. Pharmacological and non-pharmacological management aimed at improving glycaemic control in patients with T2DM is ever evolving. Over the last decade, new anti-hyperglycaemic agents have been launched that act via non-traditional mechanisms and drug development in this area remains very active.